



INTERVAL CANCER AFTER NEGATIVE FIT AND COLONOSCOPY AFTER POSITIVE FIT

The Basque Country Colorectal Cancer Screening

Isabel Portillo, Isabel Idigoras, Eunate Arana-Arri, Isabel Bilbao, Lorea Martínez-Indart, Iraide Indart, Ariane Imaz, Marta Estalella, Marta de la Cruz, Joseba Bidaurrezaga, Covadonga Audicana *et al.*

mariaisabel.portillovillares@osakidetza.eus







THE BASQUE COUNTRY CRC SCREENING

PROGRAMME

- POPULATION BASED
- 50-69 y (586.700 people)
- FIT biennial. Cut-off 20 µg Hb/g
- OC-Sensor from 2010
- Colonoscopy under sedation as confirmatory test
- Information system linked with medical database and cancer registries
- Primary Care involved
- Centralized coordination

Coverage around 100%



DEFINITION

- CANCER DIAGNOSED WITHIN 2 YEARS AFTER A NEGATIVE FIT
- CANCER DIAGNOSED AFTER NEGATIVE COLONOSCOPY

METHODOLOGY



1. BEFORE NEW INVITATION ALL SCREENED RECORDS ARE LINKED WITH:
DISCHARGES – PRINCIPAL AND SECONDARY DIAGNOSIS (ICD9-CM 1530-1548)
CANCER REGISTRIES (HOSPITAL AND POPULATION BASED REGISTRIES) – ICD10: C180-C210. M%/%%3
2. ALL NEGATIVE RESULTS AND NEGATIVE COLONOSCOPIES ARE LINKED WITH DIAGNOSED CANCER (DISCHARGES AND REGISTRIES) YEARLY
3. VOLUNTARY REPORTS (DOCTORS AND PATIENTS)

LIMITATIONS: DELAY IN REGISTRATION (CANCER AND MORTALITY REGISTRIES)

SCREENING PROGRAMME RESULTS 2009-2013

	FIRST ROUND		SECOND ROUND	
	N	%	N	%
Invited people	550,424	96.5	198,472	97.3
Participants	366,326	66.6	138,059	69.6
Positives	25,848	7.1	7,571	5.5
Colonoscopies	23,982	92.8	6,973	92.1
Advanced Adenoma	10,342	43.1	2,527	36.2
CRC	1,518	6.3	319	4.6
Stage I-II	1,015	66.9	220	69.0
Stage III-IV	436	28.7	83	26.0
Unknown	67	4.0	16	5.0
PPV for any adenoma		60.5		52.5
PPV for CRC		6.3		4.5

INTERVAL CANCERS BY FIT CUT-OFF

2009-2013 (n=135 after Negative FIT and 5 after FIT positive and negative colonoscopy)

µg Hb/g faeces (n)	AGE (years)		GENDER		LOCALIZATION			STAGE OF CRC		TIME FROM FIT TO DIAGNOSIS OF CRC (months)		
	5-59	60-69	Male	Female	Proximal	Distal	Rectum	I-II	III-IV	0-2	3-23	> 24
< 5.5 (85)	44.2	57.6	60.0	40.0	29.5	33.9	36.6	43.2	56.8	9.8	84.1	6.1
5.5-10 (19)	47.4	52.6	73.7	26.3	36.8	15.8	47.4	36.8	63.2	10.5	73.7	15.8
10-20 (31)	48.4	51.6	67.7	32.3	25.0	53.6	21.4	41.9	57.1	3.2	87.1	9.7
Total (135)	43.6	56.4	63.6	36.4	29.8	40.4	29.8	40.7	59.3	7.9	82.5	9.5
Colonoscopy negative (5)	20.0	80.0	60.0	40.0	20.0	40.0	40.0	40.0	60.0	0.0	60.0	40.0

µg Hb/g faeces	Mean age
< 5.5	60.0±4.7
5.5-10	59.4±5.1
10-20	59.8±5.5

TIME FROM FIT TO DIAGNOSIS OF CRC		
µg Hb/g faeces	Mean time	Median time
< 5.5	12.4±7.08	11.0
5.5-10	14.1±9.4	14.0
10-20	11.9±6.8	11.0

INTERVAL CANCERS BY GENDER

2009-2013

Gender	AGE (years)		FIT (µg Hb/g faeces)		LOCALIZATION			STAGE OF CRC		TIME FROM FIT TO DIAGNOSIS OF CRC (months)		
	50-60	60-69	Median	IQ	Proximal	Distal	Rectum	I-II	III-IV	0-2	3-23	> 24
Female	49.0	51.0	1.4	0.2-10	27.1	35.4	37.5	48.9	51.1	0.0	87.8	12.2
Male	40.4	59.6	2.9	2.0-12.4	36.6	32.9	30.5	40.5	59.5	12.5	79.5	8.0

Gender		Mean age
Female		59.5±5.0
Male		60.3±4.9

TIME FROM FIT TO DIAGNOSIS OF CRC		
Gender	Mean time	Median time
Female	13.7±7.1	11.0
Male	12.5±8.6	11.0

COLORECTAL CANCERS

2009-2013

		Observed Interval Cancers (140)		Screened Cancers (1,518)				Incidence Cancers distribution	
		%	n	First Round (1,518)		Second Round (319)		%	n
				%	n	%	n		
Gender*	Male	63.6	89	66.7	1,013	65.2	208	66.5	1,744
	Female	36.4	51	33.3	505	34.8	111	33.5	877
Age* (years)	50-60	43.6	61	36.6	555	34.2	109	34.9	914
	60-69	56.4	79	63.4	963	65.8	210	65.1	1,707
Localization**	Proximal	34.3	48	19.3	283	24.2	74	25.4	667
	Distal	35.0	49	65.2	954	58.5	179	49.0	1,285
	Rectum	30.7	43	15.5	227	17.3	53	25.5	669
Stage of CRC**	I-II	43.5	57	70.0	1,015	72.8	222	48.7	1,208
	III-IV	56.5	74	30.0	436	27.2	83	51.3	1,275

*No significant differences
**Significant differences

DISCUSSION

77% IC AFTER NEGATIVE FIT < 10 µg Hb/g faeces

MORE FREQUENT:

- > 60 YEARS
- MEN
- DISTAL COLON AND RECTUM

**ADVANCED STAGE
DIAGNOSED IN THE FIRST YEAR**

Sensitivity for CRC: 93%
Specificity for CRC: 97%